z-logo
Premium
Expression of CD44 isoforms and β1,6‐branched oligosaccharides in human malignant melanoma is correlated with tumor progression but not with mettastatisc potential
Author(s) -
Seelentag Walter K.F.,
Böni Roland,
Günthet Ursuls,
Futo Eva,
Burg Günther,
Heitz Philippu U.,
Roth Jürgen
Publication year - 1997
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.1600-0560.1997.tb01582.x
Subject(s) - cd44 , immunostaining , staining , pathology , melanoma , metastasis , immunohistochemistry , biology , tumor progression , cancer research , medicine , cell , cancer , genetics
CD44, a family of closely related glycoproteins generated by alternative splicing, as well as the increased β1,6‐branching of Asn‐linked oligosaccharides (β1,6‐branches), have been implicated in tumor progression and metastasis. We have investigated the expression of CD44 standard (CD44s), various CD44 splice variants (CD44v3,‐ v4,‐ v5,‐ v6 and‐ v9), and of β1,6‐branches in a total of 37 paraffin‐embedded human primary melanomas and metastases. Out of the 28 studied primary melanomas, 27 were positive for CD44s, 21 for CD44v5 (cytoplasmic staining) and 26 for β1,6 branches. Furthermore, superficial spreading melanomas showed a significant (p=0.004) stronger staining for CD44s than the thick (> 1.5 mm) nodular melanomas, whereas no significant difference was found with regard to staining for CD44v5 and β1,6‐branches. Eight of the 9 studied melanoma metastases were positive for CD44s, 6 for CD44v5 (cytoplasmic staining) and 7 for β1,6‐branches. No CD44v3, ‐v4, ‐v6 and ‐v9 could be detected in any of the tumors. On average, metastases as compared to primary tumors, exhibited a significant (p=0.002) weaker staining for CD44s. However, metastasizing melanomas could not be distinguished from non‐metastasizing ones based on CD44 immunostaining.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here